PRME

Prime Medicine, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03

Figures on this page computed 2026-11-08 13:07 UTC

Last close

4.97USD

Market data, 2026-11-04

PRME: weekly closes from 2.93 on 2026-05-15 to 4.97 on 2026-11-04, a move of +69.6%. Prices in USD.

Weekly closes, 2026-05-15 to 2026-11-04

Over that span: +69.6%

Except where said otherwise: 10-K for 2025, filed 2026-03-03

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
The filing itself
-4342.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
-3607.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.10 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.17x

1.59x

1.76x

n/a

0.72x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales2.17x
Its own average over 6 years, 2.1M.
Profit1.59x
Its own average over 7 years, -126.9M.
Free cash flow1.76x
Its own average over 7 years, -95.0M.
Debtn/a
Its own average over 1 year, 28.7M.
Price0.72x
Its own average over 5 years, 7. Market data, 2026-11-04

Sales is furthest from its own average, at 2.17 times.

The filed years, as a table

Each line is 100 at 2019-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2019-12-31	n/a	100.0
2020-12-31	100.0	2.8
2021-12-31	0.0	13.6
2022-12-31	0.0	35.4
2023-12-31	0.0	95.0
2024-12-31	57.3	123.9
2025-12-31	88.9	155.4

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001628280-26-013569
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001628280-26-013569
Reported in: USD

The filing itself

Figures behind the shape

Growth

-2.3%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate-2.3%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income-2.7%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-166.4%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
The filing itself
Return on equity-166.4%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
The filing itself
Return on assets-58.7%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
The filing itself

Margins

-4498.1%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Operating margin-4498.1%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Net margin-4342.4%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Free cash flow margin-3607.4%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself

Price

5.7x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
Price to book5.7x10-Q for 2025, filed 2026-08-06
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001628280-26-053883
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-06
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-03
The filing itself
Price to sales ratio149.3x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself

Safety

4.84

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
The filing itself
Current ratio4.8410-Q for 2025, filed 2026-08-06
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001628280-26-053883
Reported in
USD
- 10-Q for 2025, filed 2026-08-06
- 10-Q for 2025, filed 2026-08-06
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Altman Z-Score-3.25
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.